Citigroup
CERE

Citigroup’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Citigroup’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,284,070
Closed -$52.5M – 5869
2024
Q2 		$52.5M Sell
1,284,070
-611,060
-32% -$25.4M 0.03% 475
2024
Q1 		$80.1M Buy
1,895,130
+1,383,064
+270% +$58.1M 0.05% 324
2023
Q4 		$21.7M Buy
512,066
+428,280
+511% +$12.3M 0.02% 817
2023
Q3 		$1.83M Buy
83,786
+15,507
+23% +$388K ﹤0.01% 2058
2023
Q2 		$2.17M Sell
68,279
-100,510
-60% -$3.08M ﹤0.01% 2139
2023
Q1 		$4.12M Buy
168,789
+62,826
+59% +$1.84M ﹤0.01% 1605
2022
Q4 		$3.34M Sell
105,963
-33,638
-24% -$949K ﹤0.01% 1708
2022
Q3 		$3.94M Buy
139,601
+60,738
+77% +$1.81M ﹤0.01% 1684
2022
Q2 		$2.08M Buy
78,863
+58,159
+281% +$1.65M ﹤0.01% 2072
2022
Q1 		$725K Sell
20,704
-101,345
-83% -$2.96M ﹤0.01% 3236
2021
Q4 		$3.96M Sell
122,049
-74,444
-38% -$2.63M ﹤0.01% 2017
2021
Q3 		$5.8M Buy
196,493
+131,492
+202% +$3.69M ﹤0.01% 1715
2021
Q2 		$1.67M Sell
65,001
-39,272
-38% -$562K ﹤0.01% 2814
2021
Q1 		$1.43M Buy
104,273
+12,530
+14% +$183K ﹤0.01% 2715
2020
Q4 		$1.52M Buy
+91,743
New +$1.19M ﹤0.01% 3114

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Citigroup's CERE Position: Q3 2024 in Review

Citigroup sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,284,070 shares — an estimated $52.5M sold.

Citigroup first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $80.1M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Citigroup reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Citigroup sold 1,284,070 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $52.5M.
  • Citigroup first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Citigroup's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $80.1M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Citigroup's 13F filing for Q3 2024, filed 12 Nov 2024.